How can a cardioprotective treatment help protect the kidneys?

Patient Enrollment Completed in autoRIC® Trial
May 14, 2018
How can we reduce heart failure rates after heart attacks?
June 12, 2018

Contrast media used in cardiac procedures is toxic to the kidneys, especially in patients with chronic kidney disease.

The appearance of acute kidney injury, even if transient, predicts worse cardiac outcomes and higher mortality in affected patients.

Remote Ischemic Conditioning, a cardioprotective and non-invasive treatment, can also protect the kidneys against contrast-induced injury.

Euro-CRIPS, the European and Chinese cardiac and renal Remote Ischemic Preconditioning Study1, showed that remote ischemic preconditioning (RIPC) prior to percutaneous coronary intervention (PCI) protected the patient from contrast-induced nephropathy (CIN).

This multi-centre, double-blind randomized controlled trial enrolled 223 patients with moderate (Stage 3) kidney disease. Patients received standard of care treatment with or without RIC treatment.

RIC treatment reduced Contrast Induced Nephropathy by 50%, from 24.1% to 12.1%, p=0.025. Nine patients needed to be treated to avoid one event (NNT=9)

Hospitalization length, which is known to be increased in patients with CIN, was also reduced by RIC treatment (mean hospital stay 3.2 days vs. 2 days, p=0.05).


Get autoRIC®